Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Leyre Oteiza Zubiri, Ph.D., M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Frayberg M, Yung A, Zubiri L, Zlotoff DA, Reynolds KL. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. Curr Treat Options Oncol. 2021 May 26; 22(6):53. PMID: 34037918.
    Citations:    Fields:    
  2. Zubiri L, Rosovsky RP, Mooradian MJ, Piper-Vallillo AJ, Gainor JF, Sullivan RJ, Marte D, Boland GM, Gao X, Hochberg EP, Ryan DP, McEwen C, Mai M, Sharova T, Soumerai TE, Bardia A, Reynolds KL. Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. Oncologist. 2021 May 01. PMID: 33932247.
    Citations:    Fields:    
  3. Klebanov N, Pahalyants V, Murphy WS, Theodosakis N, Zubiri L, Klevens RM, Kwatra SG, Lilly E, Reynolds KL, Semenov YR. Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Oncologist. 2021 05; 26(5):e898-e901. PMID: 33783099.
    Citations: 1     Fields:    
  4. Klein IA, Rosenberg SM, Reynolds KL, Zubiri L, Rosovsky R, Piper-Vallillo AJ, Gao X, Boland G, Bardia A, Gaither R, Freeman H, Kirkner GJ, Rhee C, Klompas M, Baker MA, Wadleigh M, Winer EP, Kotton CN, Partridge AH. Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. Oncologist. 2021 Apr 15. PMID: 33856099.
    Citations:    Fields:    
  5. Molina GE, Zubiri L, Cohen JV, Durbin SM, Petrillo L, Allen IM, Murciano-Goroff YR, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Mooradian MJ, Bardia A, Mai M, Sullivan RJ, Semenov YR, Villani AC, Reynolds KL. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 Jun; 26(6):514-522. PMID: 33655682.
    Citations:    Fields:    
  6. Zlotoff DA, Hassan MZO, Zafar A, Alvi RM, Awadalla M, Mahmood SS, Zhang L, Chen CL, Ederhy S, Barac A, Banerji D, Jones-O'Connor M, Murphy SP, Armanious M, Forrestal BJ, Kirchberger MC, Coelho-Filho OR, Rizvi MA, Sahni G, Mandawat A, Tocchetti CG, Hartmann S, Gilman HK, Zatarain-Nicolás E, Mahmoudi M, Gupta D, Sullivan R, Ganatra S, Yang EH, Heinzerling LM, Thuny F, Zubiri L, Reynolds KL, Cohen JV, Lyon AR, Groarke J, Thavendiranathan P, Nohria A, Fradley MG, Neilan TG. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021 Mar; 9(3). PMID: 33653803.
    Citations:    Fields:    
  7. Kalinich M, Murphy W, Wongvibulsin S, Pahalyants V, Yu KH, Lu C, Wang F, Zubiri L, Naranbhai V, Gusev A, Kwatra SG, Reynolds KL, Semenov YR. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. J Immunother Cancer. 2021 Mar; 9(3). PMID: 33789879.
    Citations:    Fields:    
  8. Leppelmann KS, Mooradian MJ, Ganguli S, Uppot RN, Yamada K, Irani Z, Wehrenberg-Klee EP, Zubiri L, Reynolds KL, Arellano RS, Hirsch JA, Sullivan RJ, Fintelmann FJ. Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis. J Vasc Interv Radiol. 2021 02; 32(2):187-195. PMID: 33353814.
    Citations:    Fields:    Translation:Humans
  9. Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, Rose AAN, Borgers JSW, Roy S, Mangana J, Pimentel Muniz T, Cooksley T, Lupu J, Vaisman A, Saibil SD, Butler MO, Menzies AM, Carlino MS, Erdmann M, Berking C, Zimmer L, Schadendorf D, Pala L, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, Blank CU, Robert C, Sullivan RJ, Ascierto PA, Miller WH, Stephen Hodi F, Suijkerbuijk KPM, Reynolds KL, Rahma OE, Lorigan PC, Carvajal RD, Lo S, Mandala M, Long GV. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer. 2021 01; 9(1). PMID: 33468556.
    Citations: 2     Fields:    Translation:Humans
  10. Seethapathy H, Rusibamayila N, Chute DF, Lee M, Strohbehn I, Zubiri L, Faje AT, Reynolds KL, Jhaveri KD, Sise ME. Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrol Dial Transplant. 2020 Dec 29. PMID: 33374011.
    Citations:    Fields:    
  11. Drobni ZD, Zafar A, Zubiri L, Zlotoff DA, Alvi RM, Lee C, Hartmann S, Gilman HK, Villani AC, Nohria A, Groarke JD, Sullivan RJ, Reynolds KL, Zhang L, Neilan TG. Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Heart Assoc. 2020 12; 9(23):e018306. PMID: 33190570.
    Citations: 1     Fields:    Translation:HumansCells
  12. Piper-Vallillo AJ, Mooradian MJ, Meador CB, Yeap BY, Peterson J, Sakhi M, Do A, Zubiri L, Stevens S, Vaughn J, Goodwin K, Gavralidis A, Willers H, Miller A, Farago A, Piotrowska Z, Lin JJ, Dagogo-Jack I, Lennes IT, Sequist LV, Temel JS, Heist RS, Digumarthy S, Reynolds KL, Gainor JF. Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations. JTO Clin Res Rep. 2021 Jan; 2(1):100124. PMID: 33205053.
    Citations:    
  13. Durbin SM, Zubiri L, Niemierko A, Bardia A, Sullivan RJ, McEwen C, Mulvey TM, Allen IM, Lawrence DP, Cohen JV, Hochberg EP, Ryan DP, Petrillo LA, Reynolds KL. Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. Oncologist. 2021 01; 26(1):49-55. PMID: 33044765.
    Citations: 2     Fields:    
  14. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, Mosarla RC, Lee C, Zlotoff DA, Raghu VK, Hartmann SE, Gilman HK, Gong J, Zubiri L, Sullivan RJ, Reynolds KL, Mayrhofer T, Zhang L, Hoffmann U, Neilan TG. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020 Dec 15; 142(24):2299-2311. PMID: 33003973.
    Citations: 13     Fields:    
  15. Durbin SM, Mooradian MJ, Fintelmann FJ, Zubiri L, Chute DF, Kambadakone A, Pisuchpen N, Reynolds KL, Dougan M. Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. J Immunother Cancer. 2020 10; 8(2). PMID: 33033184.
    Citations:    Fields:    
  16. Cohen JV, Dougan M, Zubiri L, Reynolds KL, Sullivan RJ, Misdraji J. Liver biopsy findings in patients on immune checkpoint inhibitors. Mod Pathol. 2021 02; 34(2):426-437. PMID: 32884128.
    Citations: 4     Fields:    
  17. Seethapathy H, Zhao S, Strohbehn IA, Lee M, Chute DF, Bates H, Molina GE, Zubiri L, Gupta S, Motwani S, Leaf DE, Sullivan RJ, Rahma O, Blumenthal KG, Villani AC, Reynolds KL, Sise ME. Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. Kidney Int Rep. 2020 Oct; 5(10):1700-1705. PMID: 33102962.
    Citations: 2     
  18. Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, Zubiri L, Chen CL, Sullivan RJ, Alvi RM, Rokicki A, Murphy SP, Jones-O'Connor M, Heinzerling LM, Barac A, Forrestal BJ, Yang EH, Gupta D, Kirchberger MC, Shah SP, Rizvi MA, Sahni G, Mandawat A, Mahmoudi M, Ganatra S, Ederhy S, Zatarain-Nicolas E, Groarke JD, Tocchetti CG, Lyon AR, Thavendiranathan P, Cohen JV, Reynolds KL, Fradley MG, Neilan TG. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. Circulation. 2020 Jun 16; 141(24):2031-2034. PMID: 32539614.
    Citations: 14     Fields:    
  19. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 06 20; 395(10241):1907-1918. PMID: 32473681.
    Citations: 288     Fields:    Translation:HumansCellsPHPublic Health
  20. Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2019 Nov 21. PMID: 31754069.
    Citations:    
  21. Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020 03; 25(3):e398-e404. PMID: 32162817.
    Citations: 1     Fields:    
  22. Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, Cortazar FB, Leaf DE, Mooradian MJ, Villani AC, Sullivan RJ, Reynolds K, Sise ME. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol. 2019 12 06; 14(12):1692-1700. PMID: 31672794.
    Citations: 29     Fields:    Translation:Humans
  23. Faje A, Reynolds K, Zubiri L, Lawrence D, Cohen JV, Sullivan RJ, Nachtigall L, Tritos N. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019 Sep; 181(3):211-219. PMID: 31176301.
    Citations: 13     Fields:    Translation:Humans
  24. Molina GE, Allen IM, Hughes MS, Zubiri L, Lee H, Mooradian MJ, Reynolds KL, Dougan M, Chen ST. Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. J Am Acad Dermatol. 2020 03; 82(3):743-746. PMID: 31349048.
    Citations: 2     Fields:    Translation:Humans
  25. Hughes MS, Zheng H, Zubiri L, Molina GE, Chen ST, Mooradian MJ, Allen IM, Reynolds KL, Dougan M. Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med. 2019 Sep; 8(11):4986-4999. PMID: 31286682.
    Citations: 10     Fields:    Translation:Humans
  26. Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol. 2019 05; 94(5):563-574. PMID: 30790338.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  27. Criss SD, Mooradian MJ, Sheehan DF, Zubiri L, Lumish MA, Gainor JF, Reynolds KL, Kong CY. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. JAMA Oncol. 2019 03 01; 5(3):358-365. PMID: 30543349.
    Citations: 6     Fields:    Translation:Humans
  28. Zubiri L, Bilbao JI, Rodríguez J, Sangro B. Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors. Hepat Oncol. 2018 Apr; 5(2):HEP09. PMID: 31293777.
    Citations:    
  29. Alegre E, Zubiri L, Perez-Gracia JL, González-Cao M, Soria L, Martín-Algarra S, González A. Circulating melanoma exosomes as diagnostic and prognosis biomarkers. Clin Chim Acta. 2016 Feb 15; 454:28-32. PMID: 26724367.
    Citations: 38     Fields:    Translation:HumansCells
  30. Alegre E, Sammamed M, Fernández-Landázuri S, Zubiri L, González Á. Circulating biomarkers in malignant melanoma. Adv Clin Chem. 2015; 69:47-89. PMID: 25934359.
    Citations: 8     Fields:    Translation:HumansCells
  31. Sanmamed MF, Fernández-Landázuri S, Rodríguez C, Zárate R, Lozano MD, Zubiri L, Perez-Gracia JL, Martín-Algarra S, González A. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem. 2015 Jan; 61(1):297-304. PMID: 25411185.
    Citations: 85     Fields:    Translation:Humans
  32. Sanmamed MF, Fernández-Landázuri S, Rodríguez C, Lozano MD, Echeveste JI, Pérez Gracia JL, Alegre E, Carranza O, Zubiri L, Martín-Algarra S, González A. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Clin Chim Acta. 2014 Feb 15; 429:168-74. PMID: 24333389.
    Citations: 4     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Zubiri's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (95)
Explore
_
Co-Authors (94)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.